Search
International Breast Cancer Conference Features UCSF Health Experts
Breast cancer experts from UCSF Health will present new research and clinical findings at the annual San Antonio Breast Cancer Symposium, the world’s largest and most prestigious breast cancer conference. This year’s meeting will be held Dec. 7-10.Javid Moslehi, MD, Named Chief of the New UCSF Cardio-Oncology & Immunology Program
Javid Moslehi, MD, has been named section chief of the new Cardio-Oncology & Immunology Program at UC San Francisco, which brings together cardiologists, oncologists, immunologists and researchers to promote the cardiovascular health of patients during cancer treatment and survivorship.UCSF-Led Study Confirms Some Cancer Immunotherapies May Lead to Myocarditis and Other Potentially Serious Arrhythmias
Immune checkpoint inhibitors (ICIs) have transformed cancer care by unleashing T-cells to fight tumors, but they can cause serious cardiotoxicities including myocarditis.UCSF’s Lawrence Fong, MD, Earns NCI Award for Cancer Immunotherapy Research
The National Cancer Institute (NCI)has honored Lawrence H. Fong, MD, leader of the UC San Francisco Cancer Immunotherapy Program, with an Outstanding Investigator Award (R35).These awards support investigators who have significant records of productivity in cancer research with multiyear funding for projects of exceptional potential.An Extraordinary Response: A Young Woman’s Path to Overcoming Metastatic Colon Cancer
28-year-old woman mother of two was healthy up until a month prior, when she developed severe anemia, diarrhea and emesis, accompanied by a 25-pound weight loss.John de Groot, MD, Named Division Chief of Neuro-Oncology at UCSF
John F. de Groot, MD, has been named the new chief of the Division of Neuro-Oncology within the Department of Neurological Surgery at UC San Francisco.Breathing Easier: An Update on Diagnosis and Management of Asthma
Allergist and immunologist Monica Tang, MD, discusses keys to distinguishing asthma from other disorders.UCSF at the Forefront of New Therapies, Giving Hope to Multiple Myeloma Patients
Over the past few decades, advances in the treatment of multiple myeloma (MM) have accelerated at a thrilling pace, with a wealth of new therapeutic options now available for patients with this serious disease.UCSF Clinic Fills Unmet Need for Managing Oral Side Effects of Cancer Therapies
As advances in cancer treatments have expanded, so has the number of side effects that impact the mouth. Oral medicine specialists at UC San Francisco are working to mitigate these often-debilitating problems, which affect the majority of patients undergoing or recovering from cancer therapy.The Misery – and Consequences – of Seasonal Sneezing: How to Categorize and Care for Allergies
Otolaryngologist Anna Butrymowicz, MD, discusses the common – and growing – problem of environmental allergies, exploring reasons for the increase and looking at the impact allergies have on overall health and quality of life.Response to Cancer Immunotherapy May Be Affected by Genes We Carry from Birth
A new study finds that inherited genetic variation plays a role in who is likely to benefit from checkpoint inhibitors, which release the immune system’s brakes so it can attack cancer.Approaches to Hematologic Cancers
Jeffrey Wolf, MD, director of the Myeloma Program at UCSF Health, discusses the traditional approaches to hematologic cancers.Case Study: Multiple Myeloma and Novel Immunotherapy Approaches
Hematologist Nina Shah discusses the treatment plan of a patient diagnosed with a smoldering multiple myeloma (MM).Incorporating Clinical Trials Into Patient Care: A Unique Approach to Treating Head & Neck Cancer
With the advent of immunotherapy, UCSF physicians are incorporating clinical trials into head and neck cancer patient care and changing the treatment paradigm.CAR-T Cell Therapy Treatment and Research
UCSF is a leader in the newest forms of cellular immunotherapy, which have been shown to be particularly effective in the treatment of B-cell non-Hodgkin lymphoma (NHL) and B-cell acute lymphoblastic leukemia (B-ALL).Cancer Immunotherapy: Promise and Pitfalls
Oncologist David Oh speaks at the October 2017 Bay Area Breast Cancer Forum about key developments in immunotherapy like immune checkpoint inhibitors and T-cell therapies, plus its use in experimental approaches to breast cancer treatment.Updates from the American Society of Clinical Oncology (ASCO) 2017
A June 2017 Bay Area Breast Cancer Forum discussion of updates from the ASCO annual meeting, covering PARP inhibitors, germline BRCA mutations, HER2-positive cancer, patient-reported outcomes, immunotherapy and more. Moderator: Dr. Hope RugoThe Human Microbiome and Breast Cancer
Immunologist Michael Campbell and breast cancer surgeon Laura Esserman speak at the April 2017 Bay Area Breast Cancer Forum about the human biome, how it’s being studied and how it relates to breast cancer prevention and treatment.Multiple Myeloma: Cutting-Edge Induction and Maintenance Therapies Lead to Improved Response Rates and Survival for Newly Diagnosed Patients
Take a deep dive into therapy options for newly diagnosed myeloma patients: whether three drugs are better than two, the case for lenalidomide maintenance therapy, the many improvements in induction treatment, the future of immunotherapy, and more.